Publication | Open Access

Blockade of the ERK or PI3K–Akt signaling pathway enhances the cytotoxicity of histone deacetylase inhibitors in tumor cells resistant to gefitinib or imatinib

Epigenetic RegulationMedicineHistone Deacetylase InhibitorsTumor CellsCancer BiologyCell BiologyTumor SuppressorOncologyRadiation OncologyTumor BiologyCancer Growth